Sam

“Just on chronicity as use broadens, how much of the real-world challenge here is now kind of around tapering glucocorticoids appropriately, and how should we think about dynamic as it relates to prescribing and, I guess, potentially capping penetration down the road?”

“Back to debut, is there anything else that you're able to share on the prescribing and penetration dynamics in the quarter as it relates to community setting birth centers of excellence?”

“I was wondering if you guys can give any update on PACS, like do you guys have any insight around the outcome of the federal investigation?”

“I hope I didn't miss this, but what gave you guys the confidence around increasing your investment outlook given the uncertainty presented by the macro backdrop as well as potential credit risks stemming from tariffs?”